CHI Advisors LLC
- SEC CIK
- 0001791468
- Latest filing
- Nov 13, 2023
Holdings in Q2 2023
Holdings as of Jun 30, 2023, filed Aug 22, 2023. Long positions only; changes compare share counts with Q1 2023.
- Positions
- 25
- +2 vs. Q1 2023
- Portfolio value
- $329.4M
- −$47.2M (−12.5%) vs. Q1 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| Freeline Therapeutics Hldgs35655L206 | SPONSORED ADS | 21,666 | $55.9K | <0.1% | +21,666 | New | – |
| CRVSCorvus Pharmaceuticals, Inc. | COM | 200,000 | $458.0K | 0.1% | −2,139,402−91.5% | Reduced | History |
| LENZLENZ Therapeutics, Inc. | COM | 230,938 | $600.4K | 0.2% | +230,938 | New | History |
| HOOKHOOKIPA Pharma Inc. | COM | 788,740 | $694.1K | 0.2% | +788,740 | New | History |
| DTILPrecision Biosciences Inc | COM | 1,603,557 | $843.5K | 0.3% | −1,866,263−53.8% | Reduced | History |
| SYRSSyros Pharmaceuticals, Inc. | COM NEW | 767,445 | $2.42M | 0.7% | 00.0% | Unchanged | History |
| OVIDOvid Therapeutics Inc. | COM | 864,822 | $2.84M | 0.9% | 00.0% | Unchanged | History |
| RLYBRallybio Corp | COM | 542,774 | $3.07M | 0.9% | −217,769−28.6% | Reduced | History |
| BDTXBlack Diamond Therapeutics, Inc. | COM | 750,000 | $3.79M | 1.1% | +750,000 | New | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 85,000 | $3.92M | 1.2% | +85,000 | New | History |
| ORTXOrchard Therapeutics plc | SPON ADS NEW | 755,738 | $3.94M | 1.2% | −30,000−3.8% | Reduced | History |
| Direxion Shs ETF Tr25460G716 | DAILY S&P BIOTEC | 325,000 | $4.67M | 1.4% | +325,000 | New | – |
| IRONDisc Medicine, Inc. | COM | 125,139 | $5.56M | 1.7% | +125,139 | New | History |
| OMGAOmega Therapeutics, Inc. | COMMON STOCK | 1,055,882 | $5.91M | 1.8% | 00.0% | Unchanged | History |
| INZYInozyme Pharma, Inc. | COM | 1,195,027 | $6.66M | 2.0% | −147,164−11.0% | Reduced | History |
| TSVT2seventy bio, Inc. | COMMON STOCK | 852,007 | $8.62M | 2.6% | −2,993−0.4% | Reduced | History |
| LRMRLarimar Therapeutics, Inc. | COM | 3,414,468 | $8.72M | 2.6% | +668,203+24.3% | Added | History |
| CMPXCompass Therapeutics, Inc. | COM | 2,829,712 | $9.00M | 2.7% | 00.0% | Unchanged | History |
| IMAImageneBio, Inc. | COM | 2,122,040 | $13.9M | 4.2% | +461,168+27.8% | Added | History |
| KROSKeros Therapeutics, Inc. | COM | 402,118 | $16.2M | 4.9% | +141,059+54.0% | Added | History |
| RPTXRepare Therapeutics Inc. | COM | 2,998,734 | $31.7M | 9.6% | +7950.0% | Added | History |
| CGEMCullinan Therapeutics, Inc. | COM | 3,414,189 | $36.7M | 11.2% | +64,729+1.9% | Added | History |
| Vectivbio Hldg AGH9060V101 | ORD SHS | 2,782,756 | $46.9M | 14.3% | −2,472,728−47.1% | Reduced | – |
| SLRNACELYRIN, Inc. | COM | 2,663,806 | $55.7M | 16.9% | +2,663,806 | New | History |
| PLRXPliant Therapeutics, Inc. | COM | 3,117,017 | $56.5M | 17.1% | +115,182+3.8% | Added | History |
Options (1)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| PLRXPliant Therapeutics, Inc. | COM | – | $161.8K |
Sold out since Q1 2023 (6)
Positions held at the end of Q1 2023 that are gone from this filing.
| Security | Class | Shares in Q1 2023 | Value in Q1 2023 | % of portfolio in Q1 2023 | History |
|---|---|---|---|---|---|
| RXDXPrometheus Biosciences, Inc. | COM | 934,135 | $100.3M | 26.6% | History |
| KDNYChinook Therapeutics, Inc. | COM | 135,000 | $3.13M | 0.8% | History |
| KZRKezar Life Sciences, Inc. | COM | 689,451 | $2.16M | 0.6% | History |
| Freeline Therapeutics Hldgs35655L107 | SPONSORED ADS | 4,729,419 | $2.15M | 0.6% | – |
| TRDAEntrada Therapeutics, Inc. | COM | 56,374 | $817.4K | 0.2% | History |
| ONCROncorus, Inc. | COM | 2,367,436 | $814.6K | 0.2% | History |